Allied Blenders & Distillers has clarified that Dr. Pradipta Basu will continue to be designated and classified as a Senior Management Personnel (SMP), reversing an earlier intimation that he would cease to hold this status. The company issued the clarification on July 27, 2026, following its Board Meeting on July 23, 2026, where it had initially announced that Dr. Basu would step down from the SMP classification effective July 31, 2026. This correction ensures regulatory accuracy regarding the reporting structure and senior management composition of the group.

The clarification comes in the context of a broader leadership reorganization approved by the Board on July 23, 2026. Mr. Bikram Basu was appointed as Group Chief Marketing and Innovation Officer and SMP, effective August 1, 2026. Initially, the company stated that due to this new role, Dr. Pradipta Basu would no longer be classified as an SMP, although he would retain his position as Chief Marketing Officer. However, recognizing the roles and responsibilities discharged by Dr. Basu, the company has now confirmed that he will remain an SMP and will report directly to Mr. Bikram Basu.

Mr. Bikram Basu brings over three decades of experience in the spirits industry to his new group-level role. He previously served as Managing Director of ABD Maestro Private Limited, a subsidiary of Allied Blenders & Distillers Limited, and will continue to oversee its operations alongside his new responsibilities. His career includes six years at United Spirits, 14 years at Pernod Ricard India, and nearly 11 years with Allied Blenders. Basu holds an MBA from XLRI, Jamshedpur, a Bachelor of Commerce from St. Xavier’s College, Kolkata, and a certificate for Executive Development from INSEAD. He also serves on the Board of the Indian Association of Breweries and Distilleries (CIABC).

Dr. Pradipta Basu, who was appointed as Chief Marketing Officer and SMP on April 15, 2026, continues in his core functional role. The retention of his SMP status ensures continuity in marketing operations and aligns with the company’s focus on integrated brand strategy and innovation. The reporting hierarchy now places Dr. Basu under Mr. Bikram Basu, facilitating synergies between the group function and the subsidiary ABD Maestro Private Limited.

Key Leadership Changes

Strategic Implications

The elevation of Bikram Basu to a group-level role signals Allied Blenders & Distillers’ focus on integrated brand strategy and innovation. By combining the roles of marketing and innovation at the senior management level, the company aims to accelerate product development and market responsiveness. The correction regarding Dr. Pradipta Basu’s SMP status underscores the importance of clear reporting lines and regulatory compliance in the company’s governance framework. This structural adjustment allows for better coordination between the group’s marketing efforts and the operational oversight of ABD Maestro Private Limited.

Allied Blenders & Distillers reported a 12% year-on-year increase in standalone net profit to ₹6,899 crore for the quarter ended June 30, 2026 (Q1FY27), driven by robust volume growth and margin expansion. However, consolidated net profit attributable to owners declined 18.7% to ₹454 crore from ₹558 crore in the corresponding period of the previous year, reflecting strategic investments in advertising and promotion for its premium portfolio.

The Board of Directors approved the unaudited financial results on July 23, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by Walker Chandio & Co LLP, the statutory auditor. The company published the results in The Free Press Journal and Navshakti newspapers on July 25, 2026, under Regulation 47 of the SEBI Listing Regulations.

Financial Performance

Standalone total income rose 1.2% to ₹18,003 crore from ₹17,794 crore in Q1FY26. Gross margins expanded by 277 basis points to 46.0%, while standalone EBITDA margins widened by 113 basis points to 14.3%. Standalone EBITDA reached ₹1,400 crore, up from ₹1,220 crore in the prior year period.

Consolidated figures showed a different dynamic, with EBITDA remaining broadly flat at ₹1,200 crore against ₹1,190 crore in Q1FY26. Consolidated margins contracted by 55 basis points to 12.2%. Management attributed this contraction to increased advertising and promotion spends for the ABD Maestro portfolio and supply chain headwinds. Excluding a ₹240 million supply chain impact, like-to-like consolidated EBITDA would have been ₹1,440 crore, representing a 21.4% increase with margins at 14.7%.

Operational Highlights

The Prestige & Above (P&A) segment delivered 9.0 million cases, marking a 6.2% year-on-year increase. Volume salience for this segment increased to 48.2% from 46.2%. ICONiQ White sales surged 33.8% to 3.1 million cases from 2.3 million cases in the previous year. The company expanded its international presence to 39 countries and launched Zoya Pink, a super-premium gin extension, in Maharashtra in April 2026.

Strategic Investments and Outlook

Management outlined a multi-year capital expenditure program aimed at enhancing EBITDA margins by approximately 300 basis points by FY28 and an incremental 100 basis points by FY29. Key investments include a ₹1,150 million PET packaging unit in Telangana, operational from Q3FY26, and a ₹750 million single malt distillery in Telangana expected in H1FY27. In Maharashtra, a ₹3,400 million acquisition in MAILLP is fully operational, with capacity expanding to 61.0 MLPA.

The company targets revenue growth in the mid-teens, underpinned by increasing P&A contribution reaching ~50% by volume by FY28. It aims to drive Return on Capital Employed (ROCE) from 18.5% in FY26 to 23–25% by FY28. Net debt reduced by ₹330 million to ₹9,470 crore in June 2026, maintaining Net Debt/EBITDA at 1.7x and Net Debt/Equity at 0.6x, well within the stated framework of <2.0x and <0.75x respectively.

Regulatory Disclosures

The company continues to contest a CSD debit memorandum demanding ₹33,987.20 lakh for differential trade rates on sales between March 1, 2012, and October 31, 2017. Arbitration hearings are scheduled for July 27 and 28, 2026. Regarding income tax litigation, the department revised the aggregate demand to ₹26,075.30 lakh and interest to ₹19,377.10 lakh via an order dated January 30, 2026. All penalty proceedings under Section 271(1)(c) were dropped.